Diagnosing prostate cancer relapse

摘要

The invention discloses the use of at least one substance selected from the group consisting of Phosphatidylcholine with diacyl residue sum C24:0 (PC aa C24:0); Phosphatidylcholine with diacyl residue sum C40:3 (PC ae C40:3); Phosphatidylcholine with diacyl residue sum C40:4 (PC ae C40:4); Lysophosphatidylcholine with acyl residue sum C26:0 (lysoPC a C26:0); Lysophosphatidylcholine with acyl residue sum C6:0 (lysoPC a C6:0); 13(S)-hydroxy-9Z,11E-octadecadienoic acid (13S-HODE); 12(S)-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (12S-HETE); 15(S)-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid (15S-HETE); Leukotriene B4 (LTB4); Prostaglandin E2 (PGE2); Prostaglandin D2 (PGD2); 7±-Hydroxycholesterol (7aOHC); 7-Ketocholesterol (7KC); 5²,6²-Epoxycholesterol (5b,6b,EPC); 5±,6±-Epoxycholesterol (5a,6a,EPC); and 4²-Hydroxycholesterol (4BOHC); for prognosing relapse of a prostate cancer (PCa) in a sample of a body fluid or a tissue sample of a PCa patient.